Navigation Links
Cryo-Cell International's Stem Cell Research and Development Helps the Fight Against Breast Cancer
Date:10/6/2009

ntegral role in research to understand how C'elle stem cells might help to treat breast cancer. I continue to be inspired by all of the strong and courageous women out there who fight this disease, so it's an honor to support Susan G. Komen for the Cure," she added.

Susan G. Komen for the Cure is the world's largest grassroots network of breast cancer survivors and activists and has invested more than $1 billion since inception in 1982.

A pioneer in the non-controversial stem cell arena with its U-Cord® service for collection and cryopreservation of cord blood stem cells, Cryo-Cell has served nearly 185,000 clients worldwide. Stem cells from umbilical cord blood treat more than 75 diseases today, including sickle cell disease, several types of acute and chronic leukemias, Non-Hodgkin's lymphoma, and Hodgkin's disease. Emerging science shows great promise for potential treatments including spinal cord injury, heart disease, breast cancer, stroke, diabetes, Parkinson's disease, Alzheimer's disease and many more.

For more information, or to schedule an interview with Cryo-Cell International executives, please contact Monica Kozak at (203) 545-1055; monica@horizonmarketing.com.

About C'elle

The C'elle(SM) service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit www.celle.com.

About Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL) Based in Oldsmar, Florida, with nearly 185,000 clients worldwide, Cryo-Cell is a global leader in stem cell innovation. ISO 9001:2000 certified and accredit
'/>"/>

SOURCE Cryo-Cell International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
3. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
4. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
5. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
6. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
7. Cryo-Cell Renews Upromise Industry-Exclusive Agreement
8. Cryo-Cell International, Inc. Reports First Quarter 2009 Results
9. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
10. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... 1 safety studies, and plans for Phase 2 studies ... to be presentedCINCINNATI, May 14 Ausio Pharmaceuticals, LLC, ... aging global population, will lead off the Bio(R) Business ... 9:00 AM in Atlanta, Georgia. Ausio has developed AUS-131, ...
... Phase 3 CAPACITY results poster presentation Sunday, May 17, 8:15 ... presentation, Tuesday, May 19, 3:35 p.m. PDT - - ... - BRISBANE, Calif., May 14 InterMune, Inc. (Nasdaq: ... presentation and two poster discussion presentations related to the company,s ...
... with substantially increased capacity, for continued ... announced today robust double digit growth in sales, improved ... quarter ended March 31, 2009. , In a news ... "Our 43% growth in the first half of 2009 ...
Cached Biology Technology:Ausio Pharmaceuticals to Present at Bio(R) 2009 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 3Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 4Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... MOUNTAIN VIEW, CA January 25, 2011 23andMe,s ... both phenotypic and genetic data from 500 individuals diagnosed ... way towards its goal of building a sarcoma research ... completed its Independent Sarcoma Scientific Advisory Committee with the ...
... lethal form of brain cancer and the disease that ... efforts, even when attacked simultaneously on several fronts. One ... flexibility, discovered researchers at the Salk Institute for Biological ... glioblastoma cells can shift gears and morph into blood ...
... Baltimore, Md. (January 24, 2011) A research effort designed ... a research hatchery could end up helping Chesapeake Bay watermen ... shell crabs perishing before reaching the market. The findings, published ... that the transmission of a crab-specific virus in diseased and ...
Cached Biology News:23andMe sarcoma research community reaches 500 and announces Sarcoma Scientific Advisory Committee 2Conversion of brain tumor cells into blood vessels thwarts treatment efforts 2Conversion of brain tumor cells into blood vessels thwarts treatment efforts 3Blue crab research may help Chesapeake Bay watermen improve soft shell harvest 2
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
Biology Products: